Factor IXa inhibitors

1. A compound of Formula (I)

or a pharmaceutically acceptable salt thereof, wherein

R 1 is;

R 2 is CH or N;

R 3 is CH or N;

R 4 is CH or N;

R 5 is CH, N, or CR 8

R 6 is

1) an aryl ring, or

2) a heteroaryl ring, wherein the point of attachment to the heteroaryl ring is a carbon atom, and the heteroaryl ring is selected from the group consisting of:

a) a 5- or 6-membered unsaturated monocyclic ring with 1, 2, 3, or 4 heteroatom ring atoms selected from the group consisting of N, O or S,

b) an 9- or 10-membered unsaturated bicyclic ring with 1, 2, 3, or 4 heteroatom ring atoms selected from the group consisting of N, O or S,

said aryl and heteroaryl ring is unsubstituted, or independently mono-, di-, or tri-substituted on any carbon ring atom with R 9 ;

R 7 is —C(NR 11 )N(R 11 ) 2 , —N(R 11 ) 2 , —CN or —C 1-6 alkyl, wherein alkyl is unsubstituted or substituted at any carbon atom with —NH 2 ;

R 8 is hydrogen, halogen or C 1-6 alkyl;

R 9 , each time in which it occurs, is independently —OCF 3 , halogen, —C(O)R 10 , —C 1-6 alkyl, —N(R 12 ) 2 , or —CF 3 ;

R 10 is a 6-membered heterocycle;

R 11 , each time in which it occurs, is hydrogen or C 1-6 alkyl; and

R 12 , each time in which it occurs, is hydrogen or C 1-6 alkyl.

2. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

3. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6 is

4. A compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein R 6 is

5. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 8 is hydrogen, F or —CH 3 .

6. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is —C(NH)NH 2 , —NH 2 , —CN or —CH 2 NH 2 .

7. A compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein R 9 is —OCF 3 , F, —C(CH 3 ) 3 , —CH 2 CH 3 , —CH 3 , —N(CH 3 ) 2 , —CF 3 or

8. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is

N-(3 -aminobenzo [d]isoxazol-6-yl)-2-hydroxy-2-(4′-(trifluoromethoxy) biphenyl-3-yl)acetamide,

N-(3-aminobenzo[d]isoxazol-6-yl)-2-(4′-fluoro-3′-(morpholine-4-carbonyl)biphenyl-3-yl)-2-hydroxyacetamide,

N-(3 -aminobenzo [d]isoxazol-6-yl)-2-(4′-tert-butylbiphenyl-3 -yl)-2-hydroxyacetamide,

N-(3 -amino- 1 ,2-benzisoxazol-6-yl)-2-(4′-tert-butyl-2-fluorobiphenyl-3 -yl)-2-hydroxyacetamide,

N-(3 -amino- 1 ,2-benzisoxazol-6-yl)-2-hydroxy-2- {6-[3 -(trifluoromethyl)phenyl]pyridin-2-yl} acetamide,

N-(3 -amino- 1 ,2-benzisoxazol-6-yl)-2- [6-(4-tert-butylphenyl)pyridin-2-yl] -2-hydroxyacetamide,

9. A pharmaceutical composition comprising at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

10. A method of treating a thromboembolic disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof

11. The method of claim 10 , wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

12. The method of claim 10 , wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

13. A pharmaceutical composition comprising: a therpeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of at least one agent selected from the group consisiting of: (a) anticoagulants, (b) anti-thrombin agents, (c) anti-platelet agents, (d) fibrinolytics, (e) hypolipidemic agents, (f) antihypertensive agents, and (g) anti-ischemic agents.

14. A pharmaceutical composition comprising: a therpeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of at least one agent selected from the group consisiting of (a-1) warfarin, (a-2) heparin, (a-3) aprotinin, (a-4) synthetic pentasaccharide, (a-5) direct acting thrombin inhibitors including hirudin and argatroban, (a-6) a factor VIIa inhibitor, (a-7) a factor VIIIa inhibitor, (a-8) a factor IXa inhbitor different from the compounds of Formula (I), (a-9) a factor Xa inhibitor, (a-10) a factor XIa inhibitor, (a-11) a thrombin inhibitor, (a-12) a TAFI, (a-13) a fibrinogen inhibitor, (b-1) a boroarginine derivative, (b-2) a boropeptide, (b-3) heparin, (b-4) hirudin, (b-5) argatroban, (c-1) a NSAID, (c-2) a IIb/IIIa antagonist, (c-3) a thromboxane-A2-receptor antagonist, (c-4) a thromboxane-A2-synthetase inhibitor, (c-5) a PDE-III inhibitor, (c-6) a PDE V inhibitor, (c-7) a ADP receptor antagonist, (c-8) an antagonist of the purinergic receptor P2Y1, (c-9) an antagonist of the purinergic receptor P2Y12, (d-1) tissue plasminogen activator (TPA, natural or recombinant) and modified forms thereof, (d-2) anistreplase, (d-3) urokinase, (d-4) streptokinase, (d-5) tenecteplase (TNK), (d-6) lanoteplase (nPA), (d-7) a factor VIIa inhibitor, (d-8) a PAI-I inhibitor, (d-9) an alpha-2-antiplasmin inhibitor, (d-10) an anisoylated plasminogen streptokinase activator complex, (e-1) a HMG-CoA reductase inhibitor, (e-2) a squalene synthetase inhibitor, (e-3) a fibrate, (e-4) a bile acid sequestrant, (e-5) an ACAT inhibitor, (e-6) a MTP inhibitor, (e-7) a lipooxygenase inhibitor, (e-8) a cholesterol absorption inhibitor, (e-9) a cholesterol ester transfer protein inhibitor, (f-1) an alpha adrenergic blocker, (f-2) a beta adrenergic blocker, (f-3) a calcium channel blocker, (f-4) a diuretic, (f-5) a renin inhibitor, (f-6) an angiotensin-converting enzyme inhibitor, (f-7) an angiotensin-II-receptor antagnonist, (f-8) an ET receptor antagonist, (f-9) a Dual ET/All antagonist, (f-10) a neutral endopeptidase inhibitor, (f-11) a vasopepsidase inhibitor, (g-1) a Class I agent, (g-2) a Class II agent, (g-3) a Class III agent, (g-4) a Class IV agent, (g-5) an IAch inhibitor, (g-6) an IKur inhibitor and (g-7) a cardiac glycoside.